Clin2
NCT07672405Possibly a fitRecruiting

Sorfequiline-based treatment for new drug-sensitive TB

Tuberculosis, Pulmonary

Treatments studied

Part of Infections, Lungs & breathing clinical trials.

This study tests a new medicine called sorfequiline, given in a combination regimen, to treat adults with drug-sensitive TB. It aims to see if sorfequiline can work as well as or better than standard treatment and shorten the time to cure.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
100 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You have a new diagnosis of TB that is sensitive to the standard antibiotics (rifampin and isoniazid), or you were cured of TB before and haven't had treatment for at least 3 years.
  • You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control during the study.
  • You weigh at least 35 kilograms (about 77 pounds).
  • You do not have TB that has spread outside your lungs (extrapulmonary TB).
  • You do not have a serious heart condition or take medicines that affect your heart's rhythm.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06441006Recruiting· Phase 2/Phase 3
Personalized treatment for rifampicin-resistant TB

This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.

Ulaanbaatar
NCT07773610Not yet recruiting· Phase 2
New drug combinations for pulmonary tuberculosis

This study is testing new combinations of drugs to treat tuberculosis (TB) in the lungs. It aims to find a more effective and shorter treatment, and you may benefit from receiving these new drugs while helping advance TB research.

Cape Town, Western Cape
NCT07129629Not yet recruiting· Phase 2
Shorter TB treatment for drug-sensitive tuberculosis

This trial tests a shorter course of three drugs (bedaquiline, moxifloxacin, and pyrazinamide) for people with newly diagnosed, drug-sensitive TB. It aims to see how quickly the drugs kill the bacteria in the first few days of treatment.

NCT05454345Not yet recruiting· Phase 3
Short-course TB treatment using sitafloxacin regimens

This study tests whether adding sitafloxacin to certain short tuberculosis (TB) treatment plans can cure TB faster while staying safe. You may be eligible if you have drug-susceptible lung TB and your TB bacteria are sensitive to several specific TB medicines.

NCT05401071Recruiting· Phase 2/Phase 3
Test shorter rifapentine-based treatment for drug-sensitive TB

This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.

Guiyang, Guizhou
NCT07126639Not yet recruiting
Short-course treatment for drug-resistant tuberculosis

This trial tests a shorter treatment for drug-resistant tuberculosis (TB) using the medicine Pretomanid. It aims to find a more manageable cure for people whose TB does not respond to the standard first-line drug, rifampicin.

Hear when a new Tuberculosis, Pulmonary trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.